New gout fighter challenges standard treatment in major trial

NCT ID NCT07414394

Recruiting now Disease control Sponsor: Innovent Biologics Technology Limited (Shanghai R&D Center) Source: ClinicalTrials.gov ↗

Summary

This study aims to see if a new drug called Tigulixostat works as well or better than the standard drug Febuxostat at lowering uric acid levels in people with gout. About 600 Chinese adults with gout will take one of these drugs for 52 weeks while researchers track their uric acid levels, gout flare-ups, safety, and overall health. The main goal is to see how many people can get their uric acid below a healthy target after 24 weeks of treatment.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GOUT are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Fudan University HuaShan Hospital
RECRUITING

Shanghai, Shanghai Municipality, 200040, China

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GOUT